WO2023027088A1 - メチシリン耐性黄色ブドウ球菌(mrsa)に対する抗菌薬の薬剤感受性を向上させるための組成物、mrsa感染症を治療又は予防するための組成物及びmrsaの病原性を低下させるための組成物 - Google Patents
メチシリン耐性黄色ブドウ球菌(mrsa)に対する抗菌薬の薬剤感受性を向上させるための組成物、mrsa感染症を治療又は予防するための組成物及びmrsaの病原性を低下させるための組成物 Download PDFInfo
- Publication number
- WO2023027088A1 WO2023027088A1 PCT/JP2022/031783 JP2022031783W WO2023027088A1 WO 2023027088 A1 WO2023027088 A1 WO 2023027088A1 JP 2022031783 W JP2022031783 W JP 2022031783W WO 2023027088 A1 WO2023027088 A1 WO 2023027088A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mrsa
- composition
- bacteriophage
- drug
- phage
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 229940079593 drug Drugs 0.000 title claims abstract description 43
- 230000035945 sensitivity Effects 0.000 title claims abstract description 18
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 15
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 title claims abstract description 9
- 229960003085 meticillin Drugs 0.000 title claims abstract description 9
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 title claims description 28
- 230000001018 virulence Effects 0.000 title claims description 6
- 229940124350 antibacterial drug Drugs 0.000 title abstract description 24
- 241001515965 unidentified phage Species 0.000 claims abstract description 94
- 239000003242 anti bacterial agent Substances 0.000 claims description 32
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 12
- 239000004599 antimicrobial Substances 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 description 28
- 230000007918 pathogenicity Effects 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 25
- 238000000034 method Methods 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 21
- 230000035772 mutation Effects 0.000 description 20
- 101100393476 Escherichia coli (strain K12) gpr gene Proteins 0.000 description 19
- 101150055934 mgrA gene Proteins 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 101150022703 femA gene Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- -1 chloramphenicols Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000006137 Luria-Bertani broth Substances 0.000 description 7
- 206010000269 abscess Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 229960001019 oxacillin Drugs 0.000 description 6
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000012795 verification Methods 0.000 description 6
- 239000006142 Luria-Bertani Agar Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000003559 RNA-seq method Methods 0.000 description 5
- 229960001139 cefazolin Drugs 0.000 description 5
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000009422 growth inhibiting effect Effects 0.000 description 5
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 108700035708 EsaB Proteins 0.000 description 4
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108091030066 RNAIII Proteins 0.000 description 4
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 229960003022 amoxicillin Drugs 0.000 description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000018612 quorum sensing Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 229960005256 sulbactam Drugs 0.000 description 4
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N 6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000282579 Pan Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 101150081316 SSL11 gene Proteins 0.000 description 3
- 101710145796 Staphylokinase Proteins 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- HJJRIJDTIPFROI-NVKITGPLSA-N cefcapene Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 HJJRIJDTIPFROI-NVKITGPLSA-N 0.000 description 3
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 3
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 3
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 229960000379 faropenem Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229960002182 imipenem Drugs 0.000 description 3
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 229960002260 meropenem Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 206010034674 peritonitis Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229950009297 pivoxil Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000002132 β-lactam antibiotic Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010014603 Leukocidins Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 101710082887 Superantigen-like protein 11 Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 2
- 239000003781 beta lactamase inhibitor Substances 0.000 description 2
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 2
- 229960002966 cefcapene Drugs 0.000 description 2
- 229960004069 cefditoren Drugs 0.000 description 2
- 229960004682 cefoperazone Drugs 0.000 description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 2
- 229960005090 cefpodoxime Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940106164 cephalexin Drugs 0.000 description 2
- 150000001782 cephems Chemical class 0.000 description 2
- 229960003326 cloxacillin Drugs 0.000 description 2
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960003994 oxacillin sodium Drugs 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 2
- 229960002292 piperacillin Drugs 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000010865 sewage Substances 0.000 description 2
- VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960003865 tazobactam Drugs 0.000 description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- ADIHZDIWDRJIOQ-JFGNBEQYSA-N (2s,5r,6r)-6-[[2-(3-chlorobut-2-enylsulfanyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)CSCC=C(Cl)C)[C@H]21 ADIHZDIWDRJIOQ-JFGNBEQYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- UHHHTIKWXBRCLT-VDBOFHIQSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;ethanol;hydrate;dihydrochloride Chemical compound O.Cl.Cl.CCO.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O UHHHTIKWXBRCLT-VDBOFHIQSA-N 0.000 description 1
- ORFOPKXBNMVMKC-CEZXYXJGSA-N (6S,7S)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound CC(C)(O\N=C(/C(=O)N[C@@H]1[C@@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C([O-])=O)c1csc(N)n1)C(O)=O ORFOPKXBNMVMKC-CEZXYXJGSA-N 0.000 description 1
- XSPUSVIQHBDITA-KXDGEKGBSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 XSPUSVIQHBDITA-KXDGEKGBSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- CWXYHOHYCJXYFQ-UHFFFAOYSA-N Betamipron Chemical compound OC(=O)CCNC(=O)C1=CC=CC=C1 CWXYHOHYCJXYFQ-UHFFFAOYSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241000701553 Myoviridae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 1
- XVASOOUVMJAZNJ-MBNYWOFBSA-N Penicillin K Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)CCCCCCC)[C@H]21 XVASOOUVMJAZNJ-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 101150076271 SAK gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000018568 alpha-Defensin Human genes 0.000 description 1
- 108050007802 alpha-defensin Proteins 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960000202 aspoxicillin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
- 229960003002 atipamezole Drugs 0.000 description 1
- 229950003588 axetil Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229950007599 betamipron Drugs 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960002420 cefatrizine Drugs 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 229960001817 cefbuperazone Drugs 0.000 description 1
- SMSRCGPDNDCXFR-CYWZMYCQSA-N cefbuperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]1(OC)C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 SMSRCGPDNDCXFR-CYWZMYCQSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960002025 cefminox Drugs 0.000 description 1
- JSDXOWVAHXDYCU-VXSYNFHWSA-N cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- 229950000679 cefteram Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 cilastatin Drugs 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004244 cyclacillin Drugs 0.000 description 1
- HGBLNBBNRORJKI-WCABBAIRSA-N cyclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229940069417 doxy Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960002878 flomoxef Drugs 0.000 description 1
- UHRBTBZOWWGKMK-DOMZBBRYSA-N flomoxef Chemical compound O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229950011346 panipenem Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 238000001066 phage therapy Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229950000033 proxetil Drugs 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940041030 streptogramins Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- SNUDIPVBUUXCDG-QHSBEEBCSA-N tebipenem pivoxil Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(=O)OCOC(=O)C(C)(C)C)=O)[C@H](O)C)SC(C1)CN1C1=NCCS1 SNUDIPVBUUXCDG-QHSBEEBCSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention provides compositions for improving the drug susceptibility of antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA), compositions for treating or preventing MRSA infections, and compositions for reducing the pathogenicity of MRSA. Regarding.
- MRSA methicillin-resistant Staphylococcus aureus
- MRSA methicillin-resistant Staphylococcus aureus
- Bacteriophage is a general term for viruses that infect bacteria, and after infecting a host bacterium, it proliferates inside the bacterium. The proliferated daughter phages are released from the cell wall of the bacterium to the outside of the bacterium, and the bacterium is killed by bacteriolysis.
- bacteriophages have advantages such as that they do not affect bacterial flora other than the host pathogenic bacteria, that they are easy to grow, and that large amounts of bacteriophages can be prepared at low cost.
- Patent Document 1 S. Bacteriophages identified by Accession Nos. NITE BP-693 and NITE BP-694, respectively, have been found and reported by the present inventors as bacteriophages having the property of lysing C. aureus.
- Non-Patent Document 1 S. It has been suggested that the application of the phage PYO Sa followed by antibiotics may be more effective against C. aureus than the antibiotics alone.
- MRSA infections are diversifying. Under such circumstances, a therapeutic strategy suitable for each individual case of MRSA infection is strongly demanded, and the development of a new method for dealing with MRSA has been awaited.
- the present invention has been made in view of the above circumstances. and compositions for reducing the virulence of MRSA.
- a composition for improving drug susceptibility of an antibacterial drug against methicillin-resistant Staphylococcus aureus comprises It contains at least one bacteriophage selected from the group consisting of the bacteriophage identified by Accession No. NITE BP-693 and the bacteriophage identified by Accession No. NITE BP-694.
- the drug sensitivity is improved.
- the antibacterial agent is a ⁇ -lactam antibacterial agent.
- composition for treating or preventing MRSA infection comprises It contains at least one bacteriophage selected from the group consisting of the bacteriophage identified by accession number NITE BP-693 and the bacteriophage identified by accession number NITE BP-694, and an antibacterial agent.
- MRSA acquires resistance to the bacteriophage.
- the antibacterial agent is a ⁇ -lactam antibacterial agent.
- a composition for reducing the pathogenicity of MRSA according to the third aspect of the present invention comprises It contains at least one bacteriophage selected from the group consisting of the bacteriophage identified by Accession No. NITE BP-693 and the bacteriophage identified by Accession No. NITE BP-694.
- a composition capable of improving the drug susceptibility of an antibacterial drug to MRSA, a composition for treating or preventing MRSA infection, and a pathogenicity of MRSA Compositions can be provided for lowering.
- FIG. 10 is a graph showing verification of the growth inhibitory effect of phage ( ⁇ SA012) in MRSA wild strain.
- FIG. 10 is a graph showing verification of the growth inhibitory effect of phage ( ⁇ SA012) on ⁇ SA012-resistant MRSA (mutant: SAm1-106).
- FIG. 10 is a graph showing verification of the growth inhibitory effect of phage ( ⁇ SA012) on ⁇ SA012-resistant MRSA (mutant: SAm1-201).
- FIG. 10 is a graph showing verification of the growth inhibitory effect of phage ( ⁇ SA012) on ⁇ SA012-resistant MRSA (mutant: SAm1-201).
- FIG. 2 is a graph showing the growth inhibitory effect of adding both phages and an antibacterial drug (oxacillin) to a wild strain of MRSA from the start of the test.
- FIG. 10 is a graph showing verification of changes in expression of pathogenicity-related genes in MRSA mutants.
- FIG. 10 is a graph showing verification of changes in expression of genes related to drug efflux pumps in MRSA mutants.
- (a) is a graph showing the survival rate when a wild strain (MRSA2007-13 strain) or a phage mutant (phage-resistant strain MRSA2007-13 SAm1-201) was intraperitoneally administered to 8-week-old female BALB/c mice.
- (b) is a photographic diagram showing the macroscopic findings of lesions 7 days after subcutaneous administration of a wild strain (MRSA2007-13 strain) to an 8-week-old female BALB/c mouse, and (c) is a phage.
- Subcutaneous administration of mutant (SAm1-201), 7 days after subcutaneous administration is a photographic diagram showing the macroscopic findings of the lesion
- (d) is a graph showing the change in abscess size over 7 days after administration (mean ⁇ SE).
- composition for improving antimicrobial drug susceptibility to MRSA is a composition for improving the drug susceptibility of an antibacterial drug to methicillin-resistant Staphylococcus aureus (MRSA).
- the composition contains at least one bacteriophage selected from the group consisting of the bacteriophage identified by Accession No. NITE BP-693 and the bacteriophage identified by Accession No. NITE BP-694.
- bacteriophages which is the active ingredient of the composition of the present invention, was registered on December 25, 2008 by the Patent Microorganism Depositary Center, National Institute of Technology and Evaluation, Biotechnology Headquarters, Japan (zip code 292-0818, Chiba Prefecture, Japan). It is a bacteriophage deposited at 2-5-8 Kazusa Kamatari, Kisarazu City under the accession number NITE BP-693. The inventors named this bacteriophage " ⁇ SA012".
- the other bacteriophage which is the active ingredient of the composition of the present invention, was registered on December 25, 2008 by the National Institute of Technology and Evaluation, National Institute of Technology and Evaluation, Patent Microorganisms Depositary Center, Biotechnology Headquarters (zip code 292-0818, Chiba Prefecture, Japan). It is a bacteriophage deposited at 2-5-8 Kazusa Kamatari, Kisarazu City under the accession number NITE BP-694. The inventors named this bacteriophage " ⁇ SA039".
- ⁇ SA012 and ⁇ SA039 were both about the same size as T4 phage and slightly longer. ⁇ SA012 and ⁇ SA039 are presumed to belong to the Myoviridae family, since they have a contractile sheath. For other structures and properties of the bacteriophage according to the present invention, see JP-A-2011-50373.
- the bacteriophage according to the present invention can be obtained by making a request for distribution to the above-mentioned depositary institution where they are deposited.
- sewage running water from general households, wastewater collected from sewage treatment facilities, etc., or S.I.
- biological samples such as blood, nasal cavities, pharynx, skin, and intestinal tracts derived from animals infected with aureus, for example, the plaque assay/separation method described in JP-A-2011-50373 is used to separate and purify by a conventional method. You can also get it by
- the bacteriophage according to the present invention can be grown by a general bacteriophage growth method such as the plate lysate method described in JP-A-2011-50373.
- composition of the present invention only needs to contain the bacteriophage described above.
- examples thereof include a bacteriophage solution obtained by the proliferation method described above, and a bacteriophage solution separated from culture residue by centrifugation or the like.
- the details of the bacteriophage contained in the composition of the present invention are as described above.
- the bacteriophage contained in the composition of the present invention may be of one type (strain, strain) or may be a bacteriophage mixture (phage cocktail) of ⁇ SA012 and ⁇ SA039. It may also contain other bacteriophages.
- Other bacteriophages are not particularly limited, and include bacteriophages against bacteria different from MRSA according to the present invention (e.g., S. aureus). good.
- the concentration of the bacteriophage in the composition of the present invention is not particularly limited, and a person skilled in the art can appropriately adjust it according to the form of use. 10 3 to 1 ⁇ 10 13 PFU/mL (PFU: plaque forming unit plaque forming unit) is preferable, 1 ⁇ 10 5 to 1 ⁇ 10 11 PFU/mL is more preferable, and 1 ⁇ 10 8 to More preferably 1 ⁇ 10 10 PFU/mL.
- the method for determining that the antibacterial drug susceptibility has been improved is, for example, (i) compared to the diameter of the inhibition circle when the antibacterial drug susceptibility in MRSA is measured by the disc method (drug susceptibility test). Therefore, when the same diameter of the antibacterial drug in MRSA to which the bacteriophage according to the present invention is applied is large, it can be determined that the antibacterial drug susceptibility has been improved.
- Inhibitory Concentration MIC, when the MIC value of the antimicrobial agent in MRSA to which the bacteriophage according to the present invention is applied is smaller than the MIC value when measured by (drug susceptibility test), It can be determined that the drug sensitivity to antibacterial drugs has improved.
- MRSA may be made to acquire resistance to the bacteriophage according to the present invention, thereby improving its susceptibility to antibacterial drugs.
- "acquiring resistance” means that MRSA has resistance to the bacteriophage according to the present invention, and the bacteriophage is ineffective against MRSA (e.g., proliferation of MRSA by the bacteriophage is no longer suppressed), or the bacteriophage becomes less effective (for example, the bacteriophage suppresses the growth of MRSA to a lesser degree).
- Acquisition of resistance to bacteriophage is determined, for example, by measuring proliferation activity by EOP (plaque formation rate) or turbidity measurement method described later for MRSA to which the bacteriophage according to the present invention is applied, and applying the bacteriophage "Acquired resistance" can be determined by comparison with previous proliferative activity. Also, for example, when mutations of mgrA, femA, or both are detected by genetic analysis, it can be determined that "resistance has been acquired.”
- antibacterial agents include ⁇ -lactams, aminoglycosides, lincomycins, fosfomycins, tetracyclines, chloramphenicols, macrolides, ketolides, polypeptides, glycopeptides, streptogramins, Examples include, but are not limited to, quinolones, oxazolidinones.
- the antibacterial agent is preferably a ⁇ -lactam antibacterial agent.
- ⁇ -lactam antibacterial agents include penicillins (penicillin G, ampicillin, bacampicillin, renampicillin, cyclacillin, amoxicillin, pibmecillin, aspoxicillin, cloxacillin, piperacillin, methicillin); compound penicillin drugs (ampicillin, cloxacillin); ⁇ -lactamase inhibitors compounded penicillins (ampicillin, sulbactam, clavulanic acid, amoxicillin, piperacillin, tazobactam); cephems (cefazolin, cephalontin, cefalexin, cefatrizine, cefloxazine, cefaclor, cefadroxil, cefotiam, cefmetazole, flomoxef, cefminox, cefbuperazone, cefuroxime, axetil, cefdinir, cef
- compositions of the present invention can be used, for example, in subjects suffering from MRSA infection, such as rodents including mice, rats, hamsters and guinea pigs, primates including humans, chimpanzees and rhesus monkeys, pigs, cattle, goats, horses, It is administered to mammals such as domestic animals including sheep and birds, and pets including dogs and cats.
- MRSA infection such as rodents including mice, rats, hamsters and guinea pigs, primates including humans, chimpanzees and rhesus monkeys, pigs, cattle, goats, horses.
- mammals such as domestic animals including sheep and birds, and pets including dogs and cats.
- a preferred subject is a human.
- composition of the present invention can be prepared into dosage forms such as tablets, granules, powders, capsules, syrups, injections, etc., using an appropriate drug delivery system (DDS).
- DDS drug delivery system
- excipients, binders, lubricants, colorants, disintegrants, thickeners, preservatives, stabilizers, pH adjusters and the like that are used in ordinary pharmaceuticals can be added.
- the dosage of the composition can be appropriately set according to the subject's age, body weight, indication symptoms, and the like.
- composition for treating or preventing MRSA infection comprises at least 1 bacteriophage and an antibacterial agent.
- composition of the present invention improves the susceptibility of MRSA to antibacterial agents by the bacteriophage (same as described above) of the present invention, thereby obtaining the therapeutic or preventive effect of the antibacterial agent on MRSA infections.
- MRSA infection refers to an infection caused by MRSA, such as respiratory infection, bacteremia, infectious endocarditis, skin/soft tissue infection, intra-abdominal infection, bone ⁇ Indicates joint infections, central nervous system infections, urinary tract infections, pediatric infections, etc.
- the composition of the present invention can be used to treat or prevent these MRSA infections, and can also be used to prevent postoperative infections.
- treatment of MRSA infection refers to delay or arrest of progression of MRSA infection, remission or temporary remission of MRSA infection, recurrence of MRSA infection such as sterilization/eradication/suppression of proliferation of MRSA. It encompasses medically acceptable therapeutic interventions for various purposes, including the prevention, etc. of As used herein, “prevention of MRSA infection” includes medically acceptable prophylactic interventions for various purposes, including prevention of onset or contraction of MRSA infection, prevention of MRSA infection, and the like. .
- MRSA acquire resistance to the bacteriophage, which is the active ingredient of the composition of the present invention
- the drug susceptibility to antibacterial agents is improved, and the antibacterial agent is effective in preventing or treating MRSA infections. good too.
- the method for determining that "tolerance has been acquired" is the same as described above.
- the antibacterial agent is as described above, but it may be, for example, a ⁇ -lactam antibacterial agent.
- the details of the ⁇ -lactam antibiotics are as described above.
- compositions of the present invention can be used in subjects suffering from MRSA infection, e.g., rodents including mice, rats, hamsters and guinea pigs, primates including humans, chimpanzees and rhesus monkeys, pigs, cattle, goats, horses, sheep, It is administered to mammals such as domestic animals including birds, and pets including dogs and cats.
- MRSA infection e.g., rodents including mice, rats, hamsters and guinea pigs, primates including humans, chimpanzees and rhesus monkeys, pigs, cattle, goats, horses, sheep.
- mammals such as domestic animals including birds, and pets including dogs and cats.
- a preferred subject is a human.
- composition of the present invention can be prepared into dosage forms such as tablets, granules, powders, capsules, syrups, injections, etc., using an appropriate drug delivery system (DDS).
- DDS drug delivery system
- excipients, binders, lubricants, colorants, disintegrants, thickeners, preservatives, stabilizers, pH adjusters and the like that are used in ordinary pharmaceuticals can be added.
- the dosage of the composition can be appropriately set according to the subject's age, body weight, indication symptoms, and the like.
- Methods for administering the composition of the present invention include, for example, (i) a method of using the bacteriophage of the present invention in combination with an antibacterial agent (which may be a cocktail therapy or a combination drug), and (ii) Examples include a method of administering an antibacterial drug after administering the bacteriophage according to the present invention.
- an antibacterial agent which may be a cocktail therapy or a combination drug
- Examples include a method of administering an antibacterial drug after administering the bacteriophage according to the present invention.
- administration during meals, administration after meals, administration before meals, administration between meals, administration before bedtime, and the like are all possible.
- composition of the present invention may further contain other drugs, or may be used in combination. When used in combination, they may be administered at the same time, or may be administered one after the other.
- the "other drug” is not particularly limited as long as it does not lose the effect of improving the drug susceptibility of the bacteriophage of the present invention to the antibacterial drug, and includes anti-inflammatory agents, immunosuppressive agents, Commonly used agents for each use, such as prophylactic agents for infectious diseases, therapeutic agents for infectious diseases, insecticides, anthelmintic agents, antifungal agents, antiviral agents, etc., can be appropriately selected and used according to the mode of use. can.
- composition for reducing pathogenicity of MRSA comprises at least one selected from the group consisting of the bacteriophage identified by Accession No. NITE BP-693 and the bacteriophage identified by Accession No. NITE BP-694. of bacteriophage.
- composition of the present invention is for reducing the pathogenicity of MRSA by the bacteriophage (as described above) of the present invention.
- to reduce the pathogenicity of MRSA means to reduce the nature and ability of MRSA to infect other organisms and cause infections in the host.
- genes related to pathogenicity of MRSA for example, ⁇ EsaA ⁇ EsaB ⁇ EsaC ⁇ EssA ⁇ EssB ⁇ EssC ⁇ EsxA ⁇ EsxB ⁇ RNAIII ⁇ LukGH subunit H ⁇ LukGH subunit G ⁇ thermonuclease ⁇ Staphylococcus superantigen-like protein 11(SSL11) ⁇ Staphylokinase ⁇ staphylococcal enterotoxin type O) ⁇ is reduced, it can be determined that "the pathogenicity of MRSA is reduced.”
- the pathogenicity may be reduced by making MRSA acquire resistance to the bacteriophage. Acquisition of resistance to bacteriophage can be confirmed by the same method as described above.
- compositions of the present invention may be used, for example, in rodents including mice, rats, hamsters and guinea pigs, primates including humans, chimpanzees and rhesus monkeys, domestic animals including pigs, cattle, goats, horses, sheep and birds, dogs and cats.
- rodents including mice, rats, hamsters and guinea pigs, primates including humans, chimpanzees and rhesus monkeys, domestic animals including pigs, cattle, goats, horses, sheep and birds, dogs and cats.
- a mammal such as a companion animal, including A preferred subject is a human.
- composition of the present invention can be prepared into dosage forms such as tablets, granules, powders, capsules, syrups, injections, etc., using an appropriate drug delivery system (DDS).
- DDS drug delivery system
- excipients, binders, lubricants, colorants, disintegrants, thickeners, preservatives, stabilizers, pH adjusters and the like that are used in ordinary pharmaceuticals can be added.
- the dosage of the composition can be appropriately set according to the subject's age, body weight, indication symptoms, and the like.
- compositions containing the bacteriophage according to the present invention and improving the drug sensitivity of antimicrobial agents against MRSA.
- the drug sensitivity of the antibacterial agent is improved against MRSA, for which conventional agents did not have effects such as sterilization, eradication, and growth inhibition, and as a result, the antibacterial agent It is possible to exhibit effects such as sterilization, eradication, and suppression of proliferation against MRSA by.
- composition for treating or preventing MRSA infection according to the present invention enhances the susceptibility of MRSA to antibacterial agents by the bacteriophage of the present invention, thereby enhancing the therapeutic or preventive effect of the antibacterial agent on MRSA infection.
- the composition for reducing the pathogenicity of MRSA according to the present invention can reduce the pathogenicity of MRSA itself by the bacteriophage of the present invention, and is expected to have therapeutic or preventive effects on MRSA infections.
- the present invention also includes methods for improving drug susceptibility of antibacterial drugs to MRSA, methods for treating or preventing MRSA infections, and methods for reducing pathogenicity of MRSA, and these methods may each comprise the step of conferring MRSA resistance to the bacteriophage of the invention.
- the present inventors have previously Bacteriophages ( ⁇ SA012 and ⁇ SA039) identified by accession numbers NITE BP-693 and NITE BP-694, respectively, have been successfully isolated as bacteriophages having the property of lysing C. aureus.
- Example 1 It is known that phage-resistant bacteria change (disappear) their original functions due to resistance accompanied by genetic mutation (trade-off). Therefore, gene mutations in phage-resistant ( ⁇ SA012-resistant) MRSA were investigated.
- ⁇ SA012-resistant MRSA ( ⁇ SA012mts) was obtained as follows. 40 ⁇ L of MRSA2007-13 strain (GCA — 018409145.1) bacterial solution and 40 ⁇ L of ⁇ SA012 (10 9 PFU/mL) were mixed with 4 mL of LB liquid medium and cultured with shaking at 37° C. for 6 days. Then, the cells were collected by centrifugation, washed with 1 mL of PBS, and smeared on an LB agar medium. After overnight culture at 37°C, a single colony formed on the medium was collected, added to 3 mL of LB-Broth and cultured with shaking at 37°C overnight for cloning. The cloned strains were verified by a spot test using a soft agar LB medium and a time-lapse turbidity measurement method using a plate reader, and strains that showed no ⁇ SA012 lytic activity were used as mutants.
- mutant SAm1-201 was extracted and genomic analysis was performed using a next-generation sequencer.
- SAm1-201 was pre-cultured in LB-Broth and genome extraction was performed using the GenElute® Bacterial Genomic DNA Kit (Sigma-Aldrich) (performed according to manufacturer's instructions). Genome analysis was entrusted to Biotechnology Research Institute, Inc., and sequencing analysis was performed under the conditions of 2 ⁇ 200 bp using a next-generation sequencer DNBSEQ-G400. After removal of adapter sequences and low-quality reads using Trimmomatic (ver. 0.39), CLC Genomics Workbench 20 was used to perform mapping to reference sequences and mutation detection.
- FIG. 1(a) shows photographic diagrams of the bacteriolysis of the wild strain (“WT” in FIG. 1(b)) and mutant strains (SAm1-201 and SAm1-106).
- the test method is shown below. This test was performed by the turbidimetric method. Turbidimetry allows real-time measurement of the relationship between phage infectivity and bacterial growth. A specific method of turbidity measurement will be explained. Using a 96-well plate, the proliferative activity of the wild strain (MRSA2007-13 strain) or mutants (SAm1-201, SAm1-106) in the absence (control) or presence of ⁇ SA012 was measured using a turbidity measurement method over time. Measured by The overnight pre-cultured bacterial solution (wild strain (MRSA2007-13 strain) or mutants (SAm1-201, SAm1-106)) was diluted with LB-Broth so that OD 600 ⁇ 1.0, and Diluted 10 times.
- FIGS. 2 to 4 The results are shown in Figures 2-4.
- the vertical axis represents turbidity
- the horizontal axis represents time (h)
- gray graph lines indicate bacterial growth without phages
- black graph lines indicate bacterial growth with phages.
- the wild strain MRSA2007-13 strain
- ⁇ SA012 The wild strain (MRSA2007-13 strain) was immediately lysed by ⁇ SA012, and no increase in turbidity indicating bacterial growth was observed, confirming that phage inhibited bacterial growth (Fig. 2).
- the mutant (SAm1-106) having one mgrA mutation the degree of suppression of bacterial growth by ⁇ SA012 was weakened, and an increase in turbidity was observed at an early stage (Fig. 3).
- a mutant (SAm1-201) having mutations in both mgrA and femA showed growth similar to that of the wild type, and there was no suppression of bacterial growth by phages, confirming that the bacteria had become resistant to phages. (Fig. 4). From the above, it was confirmed that the phage ( ⁇ SA012) did not have the effect of suppressing bacterial growth in the mutant, and in particular, the mutant strain having both mgrA and femA mutations was strongly phage-resistant to MRSA. became clear.
- Example 2 In phage-resistant MRSA, it was expected that the drug sensitivity would change due to a trade-off. Therefore, we examined changes in drug sensitivity associated with phage resistance.
- the drug susceptibility of the wild type (MRSA2007-13 strain) and the mutant (SAm1-201) to ⁇ -lactam antibacterial drugs was measured by the drug susceptibility test (disk method).
- Disk method The drug susceptibility test (disk method).
- Wild type (MRSA strain 2007-13) or mutant (SAm1-201) was streaked onto LB-Agar and incubated overnight at 37°C. The next day, a single colony was picked, added to 5 mL trypticase soy broth, and cultured overnight at 37°C with shaking. After incubation, a McFarland turbidity No.
- a bacterial solution was prepared at 0.5 and spread evenly on Mueller-Hinton II agar medium using a sterile cotton swab. After placing the sensitive discs on this agar medium, they were incubated at 37° C. for 24 hours, and the diameter of the inhibition circle formed around the discs was measured in millimeters.
- the results are shown in Table 2.
- the wild strain (“WT” in Table 2) showed resistance (R) to any ⁇ -lactam antibacterial drug.
- the mutant (SAm1-201) was shown to have susceptibility (S) to ⁇ -lactam antibiotics.
- the drug susceptibility of the antibacterial drug in the wild strain (MRSA2007-13 strain) and mutant strains with both mgrA and femA mutations (SAm1-201, SAm1-206, SAm1-210) was tested by drug susceptibility test (MIC method ) was measured.
- MIC method drug susceptibility test
- the bacteriophage acquires phage resistance to MRSA, thereby improving drug sensitivity to antibacterial agents including ⁇ -lactams.
- the test method is shown below. This test was performed by the turbidimetric method.
- the bacterial solution wild strain (MRSA2007-13 strain) pre-cultured overnight was diluted with LB-Broth so that OD 600 ⁇ 1.0, and it was further diluted 10-fold ( ⁇ 1.0 ⁇ 10 8 cfu /mL).Each group was set up as follows.
- Example 4 Since mgrA is 100% mutated in the phage-resistant ( ⁇ SA012-resistant) MRSA strain, gene expression changes due to mgrA mutation were verified by RNA-seq analysis.
- RNA extraction and RNA-seq analysis are shown below. Wild strain (MRSA2007-13 strain) and phage mutant (SAm1-201) are cultured in LB-Broth until OD 600 ⁇ 1.0. After centrifuging 1 mL of the bacterial solution to obtain a pellet, the suspension is suspended in 1 mL of TRIzol Reagent (Thermo Fisher Scientific), 500 ⁇ L of Zirconia beads are added, and the bacterial cells are disrupted with a crusher. After crushing, the cells are centrifuged, the supernatant is collected, and the RNA fraction is extracted using chloroform and ethanol. Library preparation and RNA-seq analysis were entrusted to Rhelixa Corporation.
- a library was prepared using the Ribo-Zero Plus rRNA Depletion Kit and the NEBNext Ultra Directional RNA Library Prep Kit for Illumina, and sequencing analysis was performed using an Illumina NovaSeq 6000 at 150 bp ⁇ 2. After removing adapter sequences and low-quality reads using Trimmomatic (ver.0.39), they were mapped against reference sequences using HISAT2 (ver.2.1.0). After counting reads for each gene using featureCounts (ver.2.0.1), TMM normalization was performed using TCC-GUI to detect genes with altered expression.
- mgrA is said to regulate about 350 genes as a transcriptional regulatory factor, including genes related to pathogenicity and genes related to drug efflux pumps. Therefore, gene expression changes due to mgrA mutations that occur as a result of phage resistance were verified.
- T7SS consists of 4 membrane proteins (EsaA, EssA, EssB, EssC), 2 intracellular proteins (EsaB, EsaG), 5 secretory substrates (EsxA, EsxB, EsxC, EsxD, EsaD), EsaE interacting with secretory substrates.
- T7SS has an important role in the virulence of Staphylococcus aureus. It has been reported that deletion of all or specific factors (EsxA, EssB, EssC, EsxC, EsxB, EsaB, EsaD, EsaE) of T7SS reduces virulence in a mouse infection model.
- Quorum sensing is a mechanism that senses the population density of bacteria of the same species and controls the production of substances accordingly.
- Some of the virulence factors of Staphylococcus aureus are controlled by quorum sensing called the Accessory gene regulator (Agr) control system.
- Agr Accessory gene regulator
- RNAIII is transcribed, and this RNAIII directly or indirectly regulates the transcription and expression of virulence factors.
- LukGH is one of the leukocidins, also called LukAB.
- Leukocidin is a toxin component that forms pores in and destroys white blood cells such as neutrophils.
- Thermonuclease (nuc) is extracellularly secreted and can degrade extracellular DNA.
- neutrophils are known to self-destruct against Staphylococcus aureus and release their own DNA to capture the cells (NETs: neutrophil extracellular traps).
- Thermonuclease acts on NETs to help escape their capture.
- SSL Staphylococcus superantigen-like protein 11
- SSL11 suppresses immunity by suppressing the activation of neutrophils and their rolling to the vascular wall. It is also known to inhibit cell adhesion and motility.
- Staphylokinase is known to bind to plasminogen and ⁇ -defencin secreted from neutrophils.
- Sak binds to plasminogen, it becomes plasmin and is activated.
- Plasmin acts as a broad-spectrum proteolytic enzyme and contributes to the invasion of S. aureus into surrounding tissues.
- ⁇ -defensin which is an antibacterial peptide, is inactivated when it binds to sak, allowing Staphylococcus aureus to survive.
- sak gene expression is positively regulated by the Agr system, which is quorum sensing.
- ⁇ staphylococcal enterotoxin type O> SEO is an entrotoxin secreted by Staphylococcus aureus and is known to cause vomiting upon inoculation. It is also known to induce IL-1 ⁇ secretion from neutrophils via the inflammasome pathway.
- NorB and Tet are genes related to drug efflux pumps, which are genes related to drug efflux pumps, were verified by the same RNA-seq analysis as above.
- NorB and Tet are genes involved in drug efflux pumps and causative genes that cause multidrug resistance. Decreased expression of these genes increases antimicrobial susceptibility by inhibiting antimicrobial drug efflux in the bacterium.
- Example 5 From the results of RNA-seq analysis of the phage-resistant strain MRSA2007-13 SAm1-201 strain with mgrA mutation, a decrease in the expression level of various pathogenic genes was observed (Example 4). to assess the pathogenicity of phage-resistant bacteria.
- the hair from both flanks to the thigh was shaved with a hair clipper, and the skin surface was disinfected with 70% alcohol.
- 50 ⁇ L of the bacterial solution was subcutaneously administered (1.0 ⁇ 10 8 CFU/site) from both flanks to the vicinity of the thigh, and then awakened with 0.75 mg/kg atipamezole.
- the lesion was collected and minced, 200 ⁇ L of PBS and a ⁇ 5 mm zirconia ball were added, the tissue was crushed to prepare a lysate, and the number of bacteria was counted using the plate dilution method. It was measured. This animal experiment was approved by the University Animal Care and Use Committee (approval number: VH21A13).
- Figure 8(a) shows the results of pathogenicity evaluation using a mouse peritonitis model. All mice intraperitoneally administered with the wild strain (MRSA2007-13 strain) died within 24 hours (FIG. 8(a): black line). On the other hand, the 48-hour survival rate of mice administered with the phage mutant (SAm1-201) was 50% (Fig. 8(a): gray line). These results indicate that phage-resistant MRSA has reduced pathogenicity and greatly increases the survival rate of mice.
- Figures 8 (b) to (e) show the results of pathogenicity evaluation using a mouse skin abscess model.
- MRSA 2007-13 strain the wild strain
- 1 died due to sepsis-like symptoms 2 days after administration, and the left and right lesions were commissural throughout the observation period.
- the respective abscess size could not be measured.
- Mice treated with the wild-type strain (MRSA strain 2007-13) exhibited extensive tumors (FIG. 8(b)), whereas mice treated with the phage mutant (SAm1-201) exhibited limited tumor coverage. and the tumor size was remarkably small (Fig. 8(c)).
- the phage mutant (SAm1-201) was higher than the mice (Fig. 8(d): solid line) administered with the wild strain (MRSA2007-13 strain).
- the treated mice (FIG. 8(d): dashed line) showed significantly smaller tumor sizes (FIG. 8(d)).
- 7 days after administration the lesion tissue was excised, and the number of bacteria in the tissue was measured. The number of bacteria was remarkably low in the mice treated with this method, and the number of bacteria detected was about 1/50 (Fig. 8(e)).
- the phage mutant (SAm1-201) has reduced pathogenicity to mice compared to the wild type (MRSA2007-13 strain). It turns out that there is In other words, it was shown that the pathogenicity of MRSA is reduced by acquiring phage resistance of MRSA by bacteriophage ( ⁇ SA012).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
受託番号NITE BP-693で特定されるバクテリオファージ及び受託番号NITE BP-694で特定されるバクテリオファージからなる群から選択される少なくとも1のバクテリオファージを含有する。
受託番号NITE BP-693で特定されるバクテリオファージ及び受託番号NITE BP-694で特定されるバクテリオファージからなる群から選択される少なくとも1のバクテリオファージと、抗菌薬と、を含有する。
受託番号NITE BP-693で特定されるバクテリオファージ及び受託番号NITE BP-694で特定されるバクテリオファージからなる群から選択される少なくとも1のバクテリオファージを含有する。
本発明の組成物は、メチシリン耐性黄色ブドウ球菌(Methicillin-resistant Staphylococcus aureus:MRSA)に対する抗菌薬の薬剤感受性を向上させるための組成物である。該組成物は、受託番号NITE BP-693で特定されるバクテリオファージ及び受託番号NITE BP-694で特定されるバクテリオファージからなる群から選択される少なくとも1のバクテリオファージを含有する。
本発明によるMRSA感染症を治療又は予防するための組成物は、受託番号NITE BP-693で特定されるバクテリオファージ及び受託番号NITE BP-694で特定されるバクテリオファージからなる群から選択される少なくとも1のバクテリオファージと、抗菌薬と、を含有する。
本発明によるMRSAの病原性を低下させるための組成物は、受託番号NITE BP-693で特定されるバクテリオファージ及び受託番号NITE BP-694で特定されるバクテリオファージからなる群から選択される少なくとも1のバクテリオファージを含有する。
以上説明したように、本発明に係るバクテリオファージを含有する、MRSAに対する抗菌薬の薬剤感受性を向上させる組成物を提供することができる。従前の薬剤では殺菌・除菌・増殖の抑制等の効果が得られなかったMRSAに対して、本発明の組成物を用いることで、抗菌薬の薬剤感受性を向上させ、その結果、該抗菌薬によるMRSAに対する殺菌・除菌・増殖の抑制等の効果を発揮させることができる。
なお、本発明は、MRSAに対する抗菌薬の薬剤感受性を向上させるための方法、MRSA感染症を治療又は予防するための方法及びMRSAの病原性を低下させるための方法をも包含し、これらの方法は、各々、MRSAに、本発明に係るバクテリオファージに対する耐性を獲得させる工程を含んでいてもよい。
ファージ耐性化した細菌は、その遺伝子変異を伴う耐性化により本来の機能が変化(消失)することが知られている(トレードオフ)。そこで、ファージ耐性(φSA012耐性)MRSAにおける遺伝子変異を調査した。
・femA(Forward):CAAAGCCATCATTCTCACGGG(配列番号1)
・femA(Reverse):CAGAGGGGAAATAGAAAAACTGC(配列番号2)
・mgrA(Forward):GCTCAAAGACAAGTTAATCGCT(配列番号3)
・mgrA(Reverse):ATCAAATGCATGAATGACTTTACCT(配列番号4)
得られたPCR産物はFastGene Gel/PCR Extraction Kit(日本ジェネティクス株式会社)を用いて精製した(製品説明書に従って実施)。サンガー法シーケンシングは北海道システム・サイエンス株式会社に委託した
EOP=被検菌株のファージ力価/基準菌株のファージ力価
ファージ耐性化したMRSAにおいて、トレードオフにより薬剤感受性が変化することが予想された。そこで、ファージ耐性化に伴う薬剤感受性の変化について検証した。
MPIPC:オキサシリン
AMPC:アモキシリン
CEX:セファレキシン
CPDX:セフポドキシム
FRPM:ファロペネム
IPM:イミペネム
MEPM:メロペネム
AMPC:アモキシリン
CEZ:セファゾリン
MPIPC:オキサシリン
PCG:ペニシリン
S/A:スルバクタム/アンピシリン
CDTR:セフジトレン
CFPN:セフカペン
FRPM:ファロペネム
MEPM:メロペネム
IPM:イミペネム
OTC:オキシテトラサイクリン
DOXY:ドキシサイクリン
ERFX:エンロフロキサシン
ファージの耐性化によって抗菌薬の感受性の変化を引き起こすことが明らかとなったため、次に、MRSAの野生株にファージ及び抗菌薬(オキサシリン)の両方を試験開始時から添加して、増殖抑制効果を検証した。
・Control:菌90μL+SM buffer 10μL
・phi:菌90μL+φSA012 10μL(終濃度≒1.0×107pfu/m(MOI≒0.1))
・Abx:菌99μL+オキサシリンナトリウム1mL(終濃度16μg/mL)
・phi+Abx:菌89μL+phage 10μL(終濃度≒1.0×107pfu/m(MOI≒0.1))+オキサシリンナトリウム1μL(終濃度16μg/mL)
プレートをサンライズレインボーサーモRC(テカンジャパン社)にセットし、37℃で90時間振とう培養しながら波長590nmでの吸光値を15分毎に測定した。
ファージ耐性(φSA012耐性)MRSA株においてmgrAに100%変異が入ることから、mgrA変異による遺伝子発現変動をRNA-seq解析により検証した。
T7SSは4つの膜タンパク質(EsaA、EssA、EssB、EssC)、2つの細胞内タンパク質(EsaB、EsaG)、5つの分泌基質(EsxA、EsxB、EsxC、EsxD、EsaD)、分泌基質と相互作用するEsaEから構成される。T7SSは黄色ブドウ球菌の病原性を担う重要な役割を持つ。T7SSの全てまたは特定の因子(EsxA、EssB、EssC、EsxC、EsxB、EsaB、EsaD、EsaE)を欠損させると、マウス感染モデルにおいて病原性が低下するとの報告がある。
自分と同種の菌の生息密度を感知して、それに応じて物質の産生をコントロールする機構をクオラムセンシングという。黄色ブドウ球菌の病原性因子のうちいくつかはAccessory gene regulator(Agr)制御系と呼ばれるクオラムセンシングによって制御されている。クオラムセンシングによってAgr系が活性化されるとRNAIIIが転写され、このRNAIIIが直接または間接的に病原性因子の転写・発現を調節している。
LukGHはLukABとも呼ばれるロイコシジンの1種である。ロイコシジンは好中球などの白血球に孔を形成し破壊する毒素成分である。
Thermonuclease(nuc)は細胞外に分泌され、細胞外に存在するDNAを分解することができる。特に黄色ブドウ球菌に対して好中球は自滅し、自身のDNAを放出することで菌体を捕捉することが知られている(NETs:neutrophil extracellular traps)。ThermonucleaseはNETs対して作用し、その補足から逃れることを助ける。
SSLは黄色ブドウ球菌のスーパー抗原に構造が類似しているタンパク質である。SSL11は好中球の活性化や血管壁へのローリングを抑制することで免疫を抑制する。さらに細胞接着や運動性を阻害することも知られている。
Staphylokinase(sak)はプラスミノーゲン、及び好中球から分泌されるα-ディフェンシン(α-defencin)と結合することが知られている。Sakがプラスミノーゲンと結合するとプラスミンとなり活性化する。プラスミンは広域のタンパク分解酵素として働き、黄色ブドウ球菌が周囲組織に侵入するのに寄与する。また、抗菌ペプチドであるα-ディフェンシンはsakと結合するとその作用が不活化され、黄色ブドウ球菌は生存することができる。また、sakの遺伝子発現はクオラムセンシングであるAgr系によって正に制御されていることが知られている。
SEOは黄色ブドウ球菌が分泌するエントロトキシンの1種で接種すると嘔吐を引き起こすことが知られている。またインフラマソーム経路を介して好中球からのIL-1βの分泌を誘導することが知られている。
mgrA変異を有するファージ耐性菌MRSA2007-13 SAm1-201株のRNA-seq解析の結果より、様々な病原性遺伝子の発現量低下が認められた(実施例4)ため、MRSA感染症モデルマウスを用いてファージ耐性菌の病原性を評価した。
野生株(MRSA2007-13株)及びファージ変異体(ファージ耐性菌MRSA2007-13 SAm1-201)を一晩、前培養した菌液を、新しいLB brothに加え、OD600≒1.0になるまで37℃で振とう培養した。菌液を遠心分離(8,000×g、4℃、5分)して、1.0×1010CFU/mLとなるようにPBSでペレットを懸濁した。8週齢メスBALB/cマウス(三協ラボサービス、東京、日本)に、菌液100μLを腹腔内投与し(1.0×109CFU/head)、投与後48時間まで12時間おきに生存確認を行った。本動物実験は本学動物実験委員会の承認を受け、実施した(承認番号:VH21A13)。各群8頭(n=8)で試験を実施し、ログランク検定にてp<0.05の時に有意差ありとした。
野生株(MRSA2007-13株)及びファージ変異体(ファージ耐性菌MRSA2007-13 SAm1-201)を一晩、前培養した菌液を、新しいLB brothに加え、OD600≒1.0になるまで37℃で振とう培養した。菌液を遠心分離(8,000×g、4℃、5分)して、2.0×109CFU/mLとなるようにPBSでペレットを懸濁した。8週齢メスBALB/cマウス(三協ラボサービス、東京、日本)に、3種混合麻酔(0.75mg/kg メデトミジン、4mg/kg ミダゾラム、5mg/kg ブトルファノール)を腹腔内投与し、麻酔下にて両脇腹から大腿部分をバリカンにて剃毛し、70%アルコールで皮膚表面を消毒した。その後、菌液50μLを両脇腹~大腿部付近に皮下投与(1.0×108CFU/site)した後、0.75mg/kgアチパメゾールで覚醒させた。投与後は1日1回、膿瘍サイズを測定(長径(mm)×短径(mm)=mm2)した。投与後7日目に麻酔処置をしてマウスを安楽殺し、膿瘍サイズを測定するとともに、病変部を写真撮影した。また、病変部の菌数を測定するため、病変部を採取して細切し、PBS 200μLとφ5mm ジルコニアボールを入れ、組織を破砕してライセートを作製し、平板希釈法を用いて菌数を測定した。本動物実験は本学動物実験委員会の承認を受け、実施した(承認番号:VH21A13)。
(2)受託番号:NITE BP-693
(3)受託日:2008年12月25日
(4)寄託機関:独立行政法人製品評価技術基盤機構
(2)受託番号:NITE BP-694
(3)受託日:2008年12月25日
(4)寄託機関:独立行政法人製品評価技術基盤機構
Claims (8)
- 受託番号NITE BP-693で特定されるバクテリオファージ及び受託番号NITE BP-694で特定されるバクテリオファージからなる群から選択される少なくとも1のバクテリオファージを含有する、メチシリン耐性黄色ブドウ球菌(MRSA)に対する抗菌薬の薬剤感受性を向上させるための組成物。
- MRSAに、前記バクテリオファージに対する耐性を獲得させることにより、前記薬剤感受性を向上させる、
ことを特徴とする請求項1に記載の組成物。 - 前記抗菌薬は、βラクタム系抗菌薬である、
ことを特徴とする請求項1又は2に記載の組成物。 - 受託番号NITE BP-693で特定されるバクテリオファージ及び受託番号NITE BP-694で特定されるバクテリオファージからなる群から選択される少なくとも1のバクテリオファージと、抗菌薬と、を含有する、MRSA感染症を治療又は予防するための組成物。
- MRSAに、前記バクテリオファージに対する耐性を獲得させる、
ことを特徴とする請求項4に記載の組成物。 - 前記抗菌薬は、βラクタム系抗菌薬である、
ことを特徴とする請求項4又は5に記載の組成物。 - 受託番号NITE BP-693で特定されるバクテリオファージ及び受託番号NITE BP-694で特定されるバクテリオファージからなる群から選択される少なくとも1のバクテリオファージを含有する、MRSAの病原性を低下させるための組成物。
- MRSAに、前記バクテリオファージに対する耐性を獲得させることにより、前記病原性を低下させる、
ことを特徴とする請求項7に記載の組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023543941A JPWO2023027088A1 (ja) | 2021-08-25 | 2022-08-24 | |
EP22861376.6A EP4356919A1 (en) | 2021-08-25 | 2022-08-24 | Composition for improving drug sensitivity of antibacterial drug to methicillin-resistant staphylococcus aureus (mrsa), composition for treating or preventing mrsa infection, and composition for reducing virulence of mrsa |
CN202280048599.9A CN117615770A (zh) | 2021-08-25 | 2022-08-24 | 增加抗菌药物对甲氧西林耐药性金黄色葡萄球菌(mrsa)的药物敏感性的组合物、治疗或预防mrsa感染的组合物及降低mrsa毒力的组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021137252 | 2021-08-25 | ||
JP2021-137252 | 2021-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023027088A1 true WO2023027088A1 (ja) | 2023-03-02 |
Family
ID=85322802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/031783 WO2023027088A1 (ja) | 2021-08-25 | 2022-08-24 | メチシリン耐性黄色ブドウ球菌(mrsa)に対する抗菌薬の薬剤感受性を向上させるための組成物、mrsa感染症を治療又は予防するための組成物及びmrsaの病原性を低下させるための組成物 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4356919A1 (ja) |
JP (1) | JPWO2023027088A1 (ja) |
CN (1) | CN117615770A (ja) |
WO (1) | WO2023027088A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113038960A (zh) * | 2018-08-10 | 2021-06-25 | 明治制果药业株式会社 | 噬菌体剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011050373A (ja) | 2008-12-26 | 2011-03-17 | Wako Pure Chem Ind Ltd | スタフィロコッカス・アウレウス溶菌性バクテリオファージ |
JP2021137252A (ja) | 2020-03-04 | 2021-09-16 | テルモ株式会社 | 収容具および収容具用シート |
-
2022
- 2022-08-24 WO PCT/JP2022/031783 patent/WO2023027088A1/ja active Application Filing
- 2022-08-24 EP EP22861376.6A patent/EP4356919A1/en active Pending
- 2022-08-24 JP JP2023543941A patent/JPWO2023027088A1/ja active Pending
- 2022-08-24 CN CN202280048599.9A patent/CN117615770A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011050373A (ja) | 2008-12-26 | 2011-03-17 | Wako Pure Chem Ind Ltd | スタフィロコッカス・アウレウス溶菌性バクテリオファージ |
JP2021137252A (ja) | 2020-03-04 | 2021-09-16 | テルモ株式会社 | 収容具および収容具用シート |
Non-Patent Citations (10)
Title |
---|
CAPPARELLI ROSANNA, NOCERINO NUNZIA, LANZETTA ROSA, SILIPO ALBA, AMORESANO ANGELA, GIANGRANDE CHIARA, BECKER KARSTEN, BLAIOTTA GIU: "Bacteriophage-Resistant Staphylococcus aureus Mutant Confers Broad Immunity against Staphylococcal Infection in Mice", PLOS ONE, vol. 5, no. 7, 22 July 2010 (2010-07-22), pages e11720, XP093039008, DOI: 10.1371/journal.pone.0011720 * |
CHEN LE, WANG ZIHUI, XU TAO, GE HONGFEI, ZHOU FANGYUE, ZHU XIAOYI, LI XIANHUI, QU DI, ZHENG CHUNQUAN, WU YANG, ZHAO KEQING: "The Role of graRS in Regulating Virulence and Antimicrobial Resistance in Methicillin-Resistant Staphylococcus aureus", FRONTIERS IN MICROBIOLOGY, vol. 12, XP093038996, DOI: 10.3389/fmicb.2021.727104 * |
KEBRIAEI RAZIEH, LEV KATHERINE, MORRISETTE TAYLOR, STAMPER KYLE C., ABDUL-MUTAKABBIR JACINDA C., LEHMAN SUSAN M., MORALES SANDRA, : "Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 64, no. 7, 23 June 2020 (2020-06-23), US , XP093039011, ISSN: 0066-4804, DOI: 10.1128/AAC.00461-20 * |
MAIDHOF H, REINICKE B, BLÜMEL P, BERGER-BÄCHI B, LABISCHINSKI H: "femA, which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 173, no. 11, 1 June 1991 (1991-06-01), US , pages 3507 - 3513, XP093039002, ISSN: 0021-9193, DOI: 10.1128/jb.173.11.3507-3513.1991 * |
NAKAMURA, NOBUHIRO ET AL.: "A trade-off between bacteriophage resistance and virulence reduction in Staphylococcus aureus", PROGRAM • ABSTRACTS OF PSEUDOMONAS AERUGINOSA INFECTION RESEARCH GROUP; FEBRUARY 18 - 19, 2022, vol. 56, 10 February 2022 (2022-02-10) - 19 February 2022 (2022-02-19), pages 28, XP009543873 * |
NAKAMURA, NOBUHIRO ET AL.: "ODP-214/W10-7 Bacteriophage-resistant variants of MRSA are resensitized to β-lactam antibiotics", NIHON SAIKINGAKU ZASSHI - JAPANESE JOURNAL OF BACTERIOLOGY, NIHON SAIKIN GAKKAI, TOKYO, JP, vol. 77, no. 1, 21 February 2022 (2022-02-21), TOKYO, JP , pages 111, XP009543749, ISSN: 0021-4930 * |
NISHIDA, KEITA ET AL.: "Elucidation of phage resistance mechanism in Staphylococcus aureus", NIPPON JUI GAKKAI GAKUJUTSU SHUKAI KOEN YOSHISHU = PROCEEDINGS OF THE JAPANESE SOCIETY OF VETERINARY, JAPANESE SOCIETY OF VETERINARY, JP, vol. 164, 7 September 2021 (2021-09-07) - 13 September 2021 (2021-09-13), JP , pages IO, XP009543818, ISSN: 1347-8621 * |
PROC NATL ACAD SCI U S A., vol. 118, no. 10, 9 March 2021 (2021-03-09), pages e2008007118 |
TROTONDA MARÍA PILAR, XIONG YAN Q., MEMMI GUIDO, BAYER ARNOLD S., CHEUNG AMBROSE L.: "Role of mgrA and sarA in Methicillin‐Resistant Staphylococcus aureus Autolysis and Resistance to Cell Wall–Active Antibiotics", JOURNAL OF INFECTIOUS DISEASES, UNIVERSITY OF CHICAGO PRESS, US, vol. 199, no. 2, 15 January 2009 (2009-01-15), US , pages 209 - 218, XP093038998, ISSN: 0022-1899, DOI: 10.1086/595740 * |
ZSCHACH HENRIKE, LARSEN METTE, HASMAN HENRIK, WESTH HENRIK, NIELSEN MORTEN, MIĘDZYBRODZKI RYSZARD, JOŃCZYK-MATYSIAK EWA, WEBER-DĄB: "Use of a Regression Model to Study Host-Genomic Determinants of Phage Susceptibility in MRSA", ANTIBIOTICS, vol. 7, no. 1, 29 January 2018 (2018-01-29), pages 9, XP093039003, DOI: 10.3390/antibiotics7010009 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113038960A (zh) * | 2018-08-10 | 2021-06-25 | 明治制果药业株式会社 | 噬菌体剂 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2023027088A1 (ja) | 2023-03-02 |
EP4356919A1 (en) | 2024-04-24 |
CN117615770A (zh) | 2024-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Estes et al. | Present and future therapeutic strategies for melioidosis and glanders | |
Löfmark et al. | Metronidazole is still the drug of choice for treatment of anaerobic infections | |
Kamble et al. | Antibiotic tolerance in biofilm and stationary-phase planktonic cells of Staphylococcus aureus | |
JP7121954B2 (ja) | 抗細菌性薬剤併用物の組成物及び使用方法 | |
JP2021505197A (ja) | 微生物感染を防ぐための方法および組成物 | |
WO2023027088A1 (ja) | メチシリン耐性黄色ブドウ球菌(mrsa)に対する抗菌薬の薬剤感受性を向上させるための組成物、mrsa感染症を治療又は予防するための組成物及びmrsaの病原性を低下させるための組成物 | |
EP3996510A2 (en) | Live biotherapeutic compositions and methods | |
WO2022013314A1 (en) | Bacteriophage cocktails and uses thereof | |
Gajdács et al. | Insights on carbapenem-resistant Pseudomonas aeruginosa: phenotypic characterization of relevant isolates | |
Chika et al. | Phenotypic detection of AmpC enzymes and antimicrobial susceptibility of Klebsiella spp. isolated from abattoir | |
TW202122585A (zh) | 治療細菌感染的方法 | |
Yassin et al. | Prevalence of metallo-β-lactamase producing Pseudomonas aeruginosa in wound infections in Duhok City, Iraq | |
Okpa et al. | ESBL production and multidrug resistance of Salmonella serovars isolates in Benue State | |
US20040176349A1 (en) | Antibacterial composition | |
Pompilio et al. | Microbial biofilm: a “sticky” problem | |
Picoli et al. | Bacteriophages as Anti-Methicillin Re-sistant Staphylococcus aureus Agents | |
EP4265263A1 (en) | Bacteriophage suitable for treating a bacterial infection caused by pseudomonas aeruginosa | |
Bhatti et al. | Correlation of blaNDM to antibiotic resistance patterns in Klebsiella pneumoniae isolates from Tertiary Care Hospital in Lahore, Pakistan | |
Anekpo et al. | β-Lactams-Based Antibiotics Resistance: A Bottom-up Overview | |
JP2024520907A (ja) | ブドウ球菌バクテリオファージ及びその使用 | |
Pastor et al. | Antibiotic resistance profile in co-infecting bacteria isolated from sheep dipslaying orf lesions. | |
Hariri et al. | Phenotypic Detection of Metallo-Β Lactamase Producing Carbapenem-Resistant Pseudomonas Aeruginosa | |
McCullor | Bacteriophage and Phage-Like Elements of Clinically Important Streptococci: Role in Horizontal Gene Transfer and Enhanced Virulence | |
Paramitadevi et al. | Resistance profile of Escherichia coli isolated from stool, feed, and compost sources to antibiotics in Sukabumi | |
Devi et al. | Overview of Antimicrobial Resistance and mechanisms: the Relative Status of the Past and Current |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22861376 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023543941 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280048599.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022861376 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022861376 Country of ref document: EP Effective date: 20240118 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |